Seventure expects uptick in microbiome-focused VC investments

February 28, 2017 Christoph Graener

Having closed a EUR 160 million venture fund focusing exclusively on microbiome-related fields—including pharmaceuticals, nutrition, biomarkers and diagnostics—Seventure Partners president and CEO Isabelle de Cremoux tells Mike Ward, Informa Pharma Intelligence’s insights global director of content, how she expects to add another 10 companies this year to the nine she already has in her portfolio.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Isabelle de Cremoux – President and CEO, Seventure

Previous Article
Market-ready Advicenne seeks partners and EUR 40 million VC funds

With a focus on pediatric neurology and nephrology, Dr. Luc-André Granier, founder, CEO and medical directo...

Next Article
Digital medicine will drive meaningful personalized clinical outcomes

Medidata president and co-founder Glen de Vries shares his views on how digital medicine has the potential ...